Key Highlights

  • Amylyx Pharmaceuticals initiated a $350 million common stock offering.
  • The offering features a $52.5 million overallotment option.
  • Proceeds will support avexitide launch preparations and R&D expansion following its LUCIDITY Phase 3 success.
  • The company targets a late 2026 regulatory submission.

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) initiated a $350 million common stock offering, featuring a $52.5 million overallotment option, to support avexitide launch preparations and R&D expansion following its LUCIDITY Phase 3 success.

What Happened

Proceeds are earmarked for commercial scale-up and operations as the company targets a late 2026 regulatory submission for avexitide.

Market Reaction

The disclosed information does not include stock price or trading data for Amylyx Pharmaceuticals following the offering announcement.

Outlook

The planned late 2026 regulatory submission for avexitide, supported by the proceeds from this offering, represents the next major disclosed milestone for the company.